IBAB Ion Beam Applications SA

IBA - Regulated Information

IBA - Regulated Information

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, October 1st, 2024 06:00

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 26, 2024.

In its notification, Vallcara Limited indicated that following an acquisition of securities or voting rights. Its total participation in IBA SA increased and its participation in IBA shares with voting rights crossed the threshold of 3% on 24/09/2024.

Content of the notification

  • Reason for the notification: Acquisition or disposal of securities or voting rights
  • Notification by: A parent company or controlling person
  • Persons subject to the notification requirement:
  • Date on which the threshold is crossed: 24/09/2024
  • Threshold crossed (in %) : 3%
  • Denominator : 40.595.290
  • Notified details: (extract of the received notification form)
  • Full chain of controlled undertakings through which the holding is effectively held

Vallcara Limited is 100% owned by Vallgesa Limited (C 58154), a company registered in Malta. Vallgesa Limited is not a controlled entity.

  • Additional information

Vallcara Limited has reached the 3% notification threshold following the acquisition of shares. Vallcara Limited is the investment manager who can exercise voting rights at its discretion in the absence of specific.

  • About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

Valérie Van Impe

Paralegal



 

Attachment



EN
01/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Gimv: Another NAV enhancing exit - Rehaneo sold to Fremman Capital. Gimv: Oustanding NAV performance and upcoming capital increase. IBA: Nice order intake catch-up in Other Accelerators, positive REBIT expected for 2024

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Wim Lewi
 PRESS RELEASE

IBA Business Update – Third Quarter 2024

IBA Business Update – Third Quarter 2024 Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024. Group Overview Solid equipment order intake at period-end of EUR 171 million, an increase from last year. Post-period, several major contracts finalized in Industrial Solutions to bring year to date order intake to EUR 215 millionStrong backlog conversion in the third quarter with momentum expected to continue into the fourth quart...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Walmart 3Q24/25 results. IBA: Rhodotron contract to equip a sterilization facility in Mexico. NEPI Rockcastle: Sound operational momentum. UCB: Final approval for Bimzelx in the United States

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Vranken
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch